ADMA Biologics (ADMA) Projected to Post Quarterly Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) is projected to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.1648 per share and revenue of $125.3440 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting the consensus estimate of $0.19. The company had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. ADMA Biologics’s revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.11 EPS. On average, analysts expect ADMA Biologics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Performance

ADMA opened at $8.46 on Monday. The firm has a 50 day simple moving average of $8.50 and a 200 day simple moving average of $11.56. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The company has a market cap of $1.96 billion, a price-to-earnings ratio of 12.44 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93.

Insiders Place Their Bets

In other news, Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $8.01 per share, with a total value of $100,125.00. Following the purchase, the director directly owned 513,884 shares of the company’s stock, valued at $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.90% of the stock is owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Hedge funds have recently bought and sold shares of the company. Summit Securities Group LLC bought a new position in shares of ADMA Biologics during the fourth quarter worth $29,000. iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics in the 3rd quarter valued at $34,000. EverSource Wealth Advisors LLC increased its position in shares of ADMA Biologics by 385.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,180 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in ADMA Biologics by 28.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after buying an additional 700 shares during the period. Finally, Kestra Advisory Services LLC acquired a new stake in ADMA Biologics during the 4th quarter worth $72,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Negative Sentiment: The lawsuit alleges that ADMA and certain senior executives made materially misleading statements about the company’s financial condition, revenue recognition, inventory distribution and business practices. The allegations have not been proven in court. Hagens Berman ADMA class action notice
• Negative Sentiment: Additional notices cite more specific claims, including alleged channel stuffing and an undisclosed related-party distributor operating from ADMA’s headquarters. If substantiated, such claims could undermine confidence in reported sales quality and corporate governance. SueWallSt ADMA shareholder alert
• Neutral Sentiment: The reported class period runs from August 9, 2024, through March 25, 2026. Investors who acquired ADMA securities during that period have until August 10, 2026 to apply to serve as lead plaintiff; the deadline is a procedural step and does not determine the merits of the case. Kahn Swick and Foti deadline notice
• Negative Sentiment: Multiple firms—including Lowey Dannenberg, Faruqi & Faruqi, Robbins Geller, Rosen and others—are soliciting affected investors or investigating potential federal securities-law violations. The volume of notices may amplify reputational concerns and litigation overhang even though most releases repeat the same underlying allegations. Lowey Dannenberg ADMA investigation

Analysts Set New Price Targets

A number of analysts have commented on ADMA shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Mizuho cut their price target on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Canaccord Genuity Group reduced their price target on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Raymond James Financial began coverage on ADMA Biologics in a research note on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.